Heparin-induced thrombocytopenia (HIT) is a prothrombotic drug reaction caused by platelet-
activating IgG antibodies that recognize platelet factor 4 (PF4)/polyanion complexes. Platelet …

Argatroban and bivalirudin are parenteral direct inhibitors of the activity of thrombin, but,
unlike heparin, can inhibit both soluble as well as clot-bound thrombin. These agents do not …

Background Argatroban, lepirudin, desirudin, bivalirudin, and danaparoid are commonly
used to manage heparin-induced thrombocytopenia related complications. However, the …

To prevent thromboembolic events associated with heparin-induced thrombocytopenia
(HIT), patients usually are treated with argatroban, lepirudin, and bivalirudin. Here, we …

The parenterally administered direct thrombin inhibitors (DTIs) argatroban and bivalirudin
are effective anticoagulants for acute heparin-induced thrombocytopenia (HIT) treatment …

Background Heparin-induced thrombocytopenia (HIT) is a relatively uncommon condition
characterized by two exceedingly common phenomena in hospitalized patients …

Venous thromboembolism (VTE) is a frequent complication in critically ill patients and is
associated with increased rates of morbidity and mortality. The use of thromboprophylaxis to …

Purpose A quality initiative to improve the management of heparin-induced
thrombocytopenia (HIT) at an academic medical center, including the development of …

Venous thromboembolism (VTE), including deep vein thrombosis and pulmonary embolism,
is a common and potentially fatal complication in the Intensive Care Unit (ICU). Critically ill …

INTRODUCTION Bivalirudin (Angiomax), a direct thrombin inhibitor (DTI), has been
approved in 42 countries worldwide. In the United States, Argentina, and Peru it is approved …